Rigel Pharmaceuticals (RIGL) Revenue Growth (1y) (2011 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 64.24% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 7.82% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 19.04% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 3,790.58% |
| 10 | Rigel Pharmaceuticals | 551.62 Mn | 404.94 Mn | 54.21 Mn | 10.28% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.28% |
| Dec 31, 2025 | 21.19% |
| Sep 30, 2025 | 25.59% |
| Jun 30, 2025 | 176.01% |
| Mar 31, 2025 | 80.58% |
| Dec 31, 2024 | 60.92% |
| Sep 30, 2024 | 96.58% |
| Jun 30, 2024 | 37.03% |
| Mar 31, 2024 | 13.29% |
| Dec 31, 2023 | -30.20% |
| Sep 30, 2023 | 25.54% |
| Jun 30, 2023 | -9.84% |
| Mar 31, 2023 | 55.78% |
| Dec 31, 2022 | 151.25% |
| Sep 30, 2022 | 4.02% |
| Jun 30, 2022 | 13.53% |
| Mar 31, 2022 | -79.34% |
| Dec 31, 2021 | 10.62% |
| Sep 30, 2021 | 17.15% |
| Jun 30, 2021 | 63.95% |
| Mar 31, 2021 | 45.30% |
| Dec 31, 2020 | 19.81% |
| Sep 30, 2020 | -11.83% |
| Jun 30, 2020 | 53.94% |
| Mar 31, 2020 | 341.71% |
| Dec 31, 2019 | -59.32% |
| Sep 30, 2019 | 328.72% |
| Jun 30, 2019 | 482.37% |
| Dec 31, 2018 | 944.27% |
| Sep 30, 2018 | 440.56% |
| Dec 31, 2017 | -249.47% |
| Sep 30, 2017 | -76.06% |
| Mar 31, 2017 | -28.73% |
| Dec 31, 2016 | -64.86% |
| Sep 30, 2016 | -71.07% |
| Jun 30, 2016 | 65.78% |
| Mar 31, 2016 | 130.90% |
| Jun 30, 2013 | -6.67% |
| Jun 30, 2012 | 279.75% |
| Sep 30, 2011 | -93.97% |
| Jun 30, 2011 | -99.20% |